1-5 of 5
Neil Senzer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A170: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and docetaxel.

Antonio Jimeno, Neil Senzer, Wen Wee Ma, Charles Rudin, Daniel Bowles, Alex Vo, Scott Peterson, Diana Hausman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A170.
https://doi.org/10.1158/1535-7163.TARG-11-A170
Published: 12 November 2011
View article titled, Abstract A170: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and docetaxel.
Journal Articles

Abstract A174: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and cetuximab.

Neil Senzer, Daniel Bowles, Roger B. Cohen, Alex Vo, Kevin Klucher, Scott Peterson, Diana F. Hausman, Antonio Jimeno
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A174.
https://doi.org/10.1158/1535-7163.TARG-11-A174
Published: 12 November 2011
View article titled, Abstract A174: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and cetuximab.
Journal Articles

Abstract B191: Phase 1 pharmacokinetic (PK) assessments of ATI-1123, a novel human serum albumin-stabilized nanoparticle docetaxel liposomal formulation, in patients with advanced solid malignancies.

Devalingam Mahalingam, Alain Mita, Ahmed Kousba, Sushma Vemulapalli, Nicole Gallegos, Gavin Anderson, J. Charles, Jon M. Rogers, John Sarantopoulos, Monica Mita, Neil Senzer, John Nemunaitis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B191.
https://doi.org/10.1158/1535-7163.TARG-11-B191
Published: 12 November 2011
View article titled, Abstract B191: Phase 1 pharmacokinetic (PK) assessments of ATI-1123, a novel human serum albumin-stabilized nanoparticle docetaxel liposomal formulation, in patients with advanced solid malignancies.
Journal Articles

A phase 1 dose escalation study and signs of anti-metastatic activity of ARQ 197, a selective c-Met inhibitor

Lee Rosen, Neil Senzer, John Nemunaitis, Tarek Mekhail, Ronald Bukowski, Chiang Li, Nigel Rulewski, April Dovholuk, Feng Chai, Thomas Chan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B91.
Published: 01 November 2007
View article titled, A phase 1 dose escalation study and signs of anti-metastatic activity of ARQ 197, a selective c-Met inhibitor
Journal Articles

p53 therapy in a patient with Li-Fraumeni syndrome

Neil Senzer, John Nemunaitis, Michael Nemunaitis, Jeffrey Lamont, Martin Gore, Hani Gabra, Rosalind Eeles, Nayanta Sodha, Frank J. Lynch, Louis A. Zumstein, Kerstin B. Menander, Robert E. Sobol, Sunil Chada
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (5): 1478–1482.
https://doi.org/10.1158/1535-7163.MCT-07-0125
Published: 18 May 2007
View article titled, <em>p53</em> therapy in a patient with Li-Fraumeni syndrome
Open the PDF for <em>p53</em> therapy in a patient with Li-Fraumeni syndrome in another window